Johnson & Johnson announced via PRNewsWire on Thursday morning that it has asked the U.S. Food and Drug Administration (FDA) to approve CAPLYTA for treating manic or mixed episodes tied to bipolar I disorder, which would be a fifth approved use for the drug.
What happened
Johnson & Johnson said in its release that it is seeking FDA approval to expand CAPLYTA's use into bipolar mania, which would mark a fifth potential indication for the drug. The company said two Phase 3 studies found that CAPLYTA cut manic symptoms more than a placebo did, with effects showing up by day three and holding through the third week. PRNewsWire reported that CAPLYTA already carries FDA clearance for depression linked to both bipolar I and bipolar II, used either on its own or alongside other treatments, making it notable among drugs approved for that use in adults.
How the stock has moved
JNJ traded at $270.40 in pre-market trading, before the regular session opens, down 0.84% from Wednesday's close of $272.70, a decline that has held steady since the news was first reported.
| Measure | Value |
|---|---|
| Price, pre-market trading | $270.40 |
| Since the close before the first report (Wednesday, November 18, 2026) | -0.84% |
| Change from the close on Wednesday, November 18, 2026 | -0.84% |
| Market value at the close on Wednesday, November 18, 2026 | $656.47 billion |
Source: Stock quote; the close before the first report from our saved closes · as of November 19, 2026 at 8:08 AM ET · Shows what the stock did after the news was first reported, not why.
Its suppliers and customers
Among suppliers named in Johnson & Johnson's filings, Microsoft was up 1.67%, Citigroup was up 1.28%, and Martin Marietta Materials was up 1.50%, all outside the regular session. Intra-Cellular Therapies and Halda Therapeutics, also listed as suppliers, and Intra-Cellular Therapies and Shockwave, listed as customers, showed no trading activity since their last close.
| Company | Role | Stock | Since last close |
|---|---|---|---|
| Microsoft | Supplier | MSFT | +1.67% |
| Citigroup | Supplier | C | +1.28% |
| Martin Marietta Materials | Supplier | MLM | +1.50% |
| Intra-Cellular Therapies | Customer | Not listed | — |
| Shockwave | Customer | Not listed | — |
| Intra-Cellular Therapies | Supplier | Not listed | — |
| Halda Therapeutics | Supplier | Not listed | — |
Source: Relationships named in company filings (Earnings call transcript; SEC 10-K annual report); stock quotes · as of November 19, 2026 at 8:08 AM ET · A supplier or customer moving the same day is not evidence that one move caused the other.